The therapeutic potential of relaxin for heart failure with preserved ejection fraction

27 August 2022 (09:48 - 10:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Guy Salama

Upmc University Of Pittsburgh Medical Center, Pittsburgh (United States of America)

4 More presentations in this session

Presentation thumbnail

Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial

Mr A. van de Bovenkamp (Amsterdam, NL)

Abstract Slides Video

Presentation thumbnail

Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial

Associate Professor R. Wachter (Leipzig, DE)

Abstract Slides Video

Presentation thumbnail

Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial

Professor J. Butler (Dallas, US)

Abstract Slides Video

Presentation thumbnail

Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction

Doctor F. Lindberg (Stockholm, SE)

Abstract Slides Video

Access the full session

Session thumbnail

HFpEF and HFmrEF: what’s new in treatment?

The Event

Event poster

ESC Congress 2022

27 August 2022 09:48 CET

You may be interested in

Congress Presentation

Daily Subcutaneous injections of Relaxin is a therapy for heart failure with preserved ejection fraction

Congress Presentation

RELAXIN-LA in worsening HFpEF

Congress Presentation

Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources